Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route


Affiliations
1 Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India
     

   Subscribe/Renew Journal


Toxicity of a substance is nothing but unwanted or series of adverse events that was initiated after administration of particular chemical, physical or biological agent. Acute toxicity study aim is to determine the occurred toxic manifestation of the administered test substance after expose to animals in one or more doses for a period of 14 days. The study provides the information or determination of therapeutic index, i.e. T.I. = LD50/ ED 50. Sub-acute toxicity testing evaluates the toxic effects of drug on repeated exposure and also provides the information on delayed and cumulative effect of the chemicals on the tissues or other biochemical mechanisms Depression is one of the most common psychiatric disorders. The symptoms of depression are often subtle and unrecognized both by patients and by physicians. Major depression remains difficult to treat, despite the wide array of registered antidepressant. Milnacipran is indicated for the treatment of major depressive disorder and management of fibromyalgia. Milnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitter.

Keywords

Milancipran, Depression, Acute Toxicity, Sub-Acute Toxicity
Subscription Login to verify subscription
User
Notifications
Font Size


  • Psychology and the National Institute of Mental Health: A Historical Analysis of Science, Practice, and Policy, Edited by Wade E. Pickren, PhD and Stanley F. Schneider, PhD, American Psychological Association, 2004.

  • The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity… Journal of affective disorders, 66(2–3): 2001, 159–64.

  • The internal and external validity of the Major Depression Inventory in measuring severity of depressive states... Psychological medicine, 33(2): 2003, 351– 356.

  • Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M, Psychiatric Diagnosis in Child and Adolescent Sucide. Archives of general psychiatry, 53(4): 1996, 339-348.

  • March J, Silva S, Petrycki S, Curry J, Wells K, Fiarbank J, Burns B, Bomino M, Mcnulty S, Vitiello B, Severe J. Treatment for Adolescent with Depression Study (TADS) Team. Journal of the American Medical Association, 292(7): 2004, 807-820.

  • HP Rang, MM Dale, JM Ritter, RJ Flower; RANG and DALE’s Pharmacology. 6thedition. New Delhi: Elsevier; P.557-574, 2007.

  • The complete drug reference by Martindale (13th edition) Pharmaceutical press, Page no- 372-375,409, 2005.

  • Hussam A. Yacoub, DO, MS, William G. Johnson, MD and Nizar Souayah, MD; Serotonin Syndrome After Administration of Milnacipran For Fibromyalgia; American Academy of Neurology; Neurology 23, 2010, Vol. 74.

  • Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. "Biochemical profile of midalcipran (F 2207), 1-phenyl-1- diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug". Neuropharmacology 24 (12): 1985, 1211– 9.

  • Briley M, Prost JF, Moret C. "Preclinical pharmacology of Milnacipran". International clinical psychopharmacology 11 Suppl 4: 1996. 9–14.

  • R Michael Gendreau, Michael D Thorn, Judy F Gendreau, Jay D Kranzler; Efficacy of Milnacipran in patients with fibromyalgia, The Journal of Rheumatology ;Vol. 32 no. 10 , 2011, 1975-1985.

  • Spencer C.M.; Wilde M.I; Milnacipran: A Review of its Use in Depression; Volume 56, Number 3, 1998, Page. 405-427(23).

  • Mike Briley; Clinical experience with dual action antidepressants in different chronic pain syndromes; Human Psycho and Experimental Pharmacology; Article first published online: 20 SEP 2004, DOI: 10.1002/hup.621

  • Anna M Redmond, John P Kelly, Brian E Leonard, The Determination of the Optimal Dose of Milnacipran in the Olfactory Bulbectomized Rat Model of Depression; Pharmacology Biochemistry and Behavior; Volume 62, Issue 4, April 1999, Pages 619–623.

  • S.Neil Vaishnavi, Charles B Nemeroff, Susan J Plott, Srinivas G Rao, Jay Kranzler, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity; Biological Psychiatry; Volume 55, Issue 3, 1 February 2004, Pages 320–322.


Abstract Views: 295

PDF Views: 0




  • Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route

Abstract Views: 295  |  PDF Views: 0

Authors

D. Benito Johnson
Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India
R. Suresh
Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India
Prakash Rao Prathima
Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India
R. Venkatnarayanan
Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India
P. M. Ashir Ahammad
Department of Pharmacology, R.V.S. College of Pharmaceutical Sciences, Sulur, Coimbatore, Tamil Nadu, India

Abstract


Toxicity of a substance is nothing but unwanted or series of adverse events that was initiated after administration of particular chemical, physical or biological agent. Acute toxicity study aim is to determine the occurred toxic manifestation of the administered test substance after expose to animals in one or more doses for a period of 14 days. The study provides the information or determination of therapeutic index, i.e. T.I. = LD50/ ED 50. Sub-acute toxicity testing evaluates the toxic effects of drug on repeated exposure and also provides the information on delayed and cumulative effect of the chemicals on the tissues or other biochemical mechanisms Depression is one of the most common psychiatric disorders. The symptoms of depression are often subtle and unrecognized both by patients and by physicians. Major depression remains difficult to treat, despite the wide array of registered antidepressant. Milnacipran is indicated for the treatment of major depressive disorder and management of fibromyalgia. Milnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitter.

Keywords


Milancipran, Depression, Acute Toxicity, Sub-Acute Toxicity

References